Zeruesenay Desta

12.2k total citations · 6 hit papers
171 papers, 8.6k citations indexed

About

Zeruesenay Desta is a scholar working on Pharmacology, Genetics and Oncology. According to data from OpenAlex, Zeruesenay Desta has authored 171 papers receiving a total of 8.6k indexed citations (citations by other indexed papers that have themselves been cited), including 79 papers in Pharmacology, 49 papers in Genetics and 44 papers in Oncology. Recurrent topics in Zeruesenay Desta's work include Pharmacogenetics and Drug Metabolism (77 papers), Estrogen and related hormone effects (47 papers) and HIV/AIDS drug development and treatment (33 papers). Zeruesenay Desta is often cited by papers focused on Pharmacogenetics and Drug Metabolism (77 papers), Estrogen and related hormone effects (47 papers) and HIV/AIDS drug development and treatment (33 papers). Zeruesenay Desta collaborates with scholars based in United States, Canada and Brazil. Zeruesenay Desta's co-authors include David A. Flockhart, Bryan A. Ward, Nadia Soukhova, Todd C. Skaar, Jae‐Gook Shin, X.-J. Zhao, James M. Rae, Anne Nguyen, David R. Jones and Stephen D. Hall and has published in prestigious journals such as Circulation, Nature Communications and Journal of Clinical Oncology.

In The Last Decade

Zeruesenay Desta

165 papers receiving 8.4k citations

Hit Papers

CYP2D6 Genotype, Antidepressant Use, and Tamoxifen Metabo... 2002 2026 2010 2018 2005 2002 2005 2003 2020 200 400 600
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. CYP2D6 Genotype, Antidepressant Use, and Tamoxifen Metabolism During Adjuvant Breast Cancer Treatment
    2005 681 citations Zeruesenay Desta, Vered Stearns et al. profile →
  2. Clinical Significance of the Cytochrome P450 2C19 Genetic Polymorphism
    2002 669 citations Zeruesenay Desta, David A. Flockhart et al. profile →
  3. Pharmacogenetics of Tamoxifen Biotransformation Is Associated With Clinical Outcomes of Efficacy and Hot Flashes
    2005 567 citations Matthew P. Goetz, James M. Rae et al. profile →
  4. The Cytochrome P450 2B6 (CYP2B6) Is the Main Catalyst of Efavirenz Primary and Secondary Metabolism: Implication for HIV/AIDS Therapy and Utility of Efavirenz as a Substrate Marker of CYP2B6 Catalytic Activity
    2003 502 citations Bryan A. Ward, David R. Jones et al. profile →
  5. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing
    2020 194 citations Zeruesenay Desta, Andrea Gaedigk et al. Clinical Pharmacology & Therapeutics profile →
  6. PharmVar GeneFocus: CYP2B6
    2021 178 citations Zeruesenay Desta, Li Gong et al. Clinical Pharmacology & Therapeutics profile →

Peers

Zeruesenay Desta
David A. Flockhart United States
Michelle Whirl‐Carrillo United States
Ron H. N. van Schaik Netherlands
Stuart A. Scott United States
Kathrin Klein Germany
Andrea Gaedigk United States
J. Steven Leeder United States
Jürgen Brockmöller Germany
Katrin Sangkuhl United States
Ingolf Cascorbi Germany
David A. Flockhart United States
Zeruesenay Desta
Citations per year, relative to Zeruesenay Desta Zeruesenay Desta (= 1×) peers David A. Flockhart

Countries citing papers authored by Zeruesenay Desta

Since Specialization
Citations

This map shows the geographic impact of Zeruesenay Desta's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Zeruesenay Desta with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Zeruesenay Desta more than expected).

Fields of papers citing papers by Zeruesenay Desta

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Zeruesenay Desta. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Zeruesenay Desta. The network helps show where Zeruesenay Desta may publish in the future.

Co-authorship network of co-authors of Zeruesenay Desta

This figure shows the co-authorship network connecting the top 25 collaborators of Zeruesenay Desta. A scholar is included among the top collaborators of Zeruesenay Desta based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Zeruesenay Desta. Zeruesenay Desta is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Collins, Kimberly S., Blessed Winston Aruldhas, Ingrid F. Metzger, et al.. (2025). A Population Pharmacokinetic Approach to Understand the Effect of Efavirenz on CYP3A Activity in Healthy Volunteers Using Midazolam as a Probe. CPT Pharmacometrics & Systems Pharmacology. 14(12). 2095–2106.
2.
Eadon, Michael T., David W. Hein, Michael Asger Andersen, et al.. (2025). Clinical Pharmacogenetics Implementation Consortium Guideline for NAT2 Genotype and Hydralazine Therapy. Clinical Pharmacology & Therapeutics. 118(6). 1430–1436.
3.
Eum, Seenae, Zeruesenay Desta, Rachel F. Tyndale, et al.. (2024). Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2B6 Genotype and Methadone Therapy. Clinical Pharmacology & Therapeutics. 116(4). 932–938. 9 indexed citations
4.
Poweleit, Ethan A., Samuel Vaughn, Zeruesenay Desta, et al.. (2024). Machine Learning‐Based Prediction of Escitalopram and Sertraline Side Effects With Pharmacokinetic Data in Children and Adolescents. Clinical Pharmacology & Therapeutics. 115(4). 860–870. 6 indexed citations
5.
Haddad, Tufia C., Vera J. Suman, Karthik V. Giridhar, et al.. (2024). Anastrozole Dose Escalation for Optimal Estrogen Suppression in Postmenopausal Early-Stage Breast Cancer: A Prospective Trial. Clinical Cancer Research. 30(15). 3147–3156. 3 indexed citations
6.
Gupta, Samir K., Allon N. Friedman, & Zeruesenay Desta. (2024). The steady-state pharmacokinetics of fixed-dose combination dolutegravir+rilpivirine in hemodialysis. AIDS. 39(4). 356–361.
7.
Liang, Tiebing, Joseph Ipe, Sha Cao, et al.. (2023). Clinically important alterations in pharmacogene expression in histologically severe nonalcoholic fatty liver disease. Nature Communications. 14(1). 1474–1474. 23 indexed citations
8.
Ly, Reynold C., Santosh Philips, Milan Radovich, et al.. (2022). Clinical Opportunities for Germline Pharmacogenetics and Management of Drug-Drug Interactions in Patients With Advanced Solid Cancers. JCO Precision Oncology. 6(6). e2100312–e2100312. 11 indexed citations
9.
Vreeman, Rachel, Winstone Nyandiko, Patrick O. Monahan, et al.. (2022). Predicting neurodevelopmental risk in children born to mothers living with HIV in Kenya: protocol for a prospective cohort study (Tabiri Study). BMJ Open. 12(4). e061051–e061051. 4 indexed citations
10.
Metzger, Ingrid F., et al.. (2019). CYP2B6 Genotype‐Dependent Inhibition of CYP1A2 and Induction of CYP2A6 by the Antiretroviral Drug Efavirenz in Healthy Volunteers. Clinical and Translational Science. 12(6). 657–666. 10 indexed citations
11.
Desta, Zeruesenay, Roseann S. Gammal, Li Gong, et al.. (2019). Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2B6 and Efavirenz‐Containing Antiretroviral Therapy. PMC. 19 indexed citations
12.
Gufford, Brandon T., Jason Robarge, Michael T. Eadon, et al.. (2018). Rifampin modulation of xeno‐ and endobiotic conjugating enzymemRNAexpression and associated microRNAs in human hepatocytes. Pharmacology Research & Perspectives. 6(2). e00386–e00386. 22 indexed citations
13.
Gufford, Brandon T., Jason Robarge, Michael T. Eadon, et al.. (2018). Rifampin modulation of xeno- and endobiotic conjugating enzyme mRNA expression and associated microRNAs in human hepatocytes. PMC. 3 indexed citations
14.
Lu, Jessica Bo Li, Heather A. Jaynes, Jason Robarge, et al.. (2016). Efavirenz inhibits the human ether-a-go-go related current (hERG) and induces QT interval prolongation in CYP2B6*6*6 allele carriers. PMC. 5 indexed citations
15.
Robarge, Jason, Ingrid F. Metzger, Jessica Bo Li Lu, et al.. (2016). Population Pharmacokinetic Modeling To Estimate the Contributions of Genetic and Nongenetic Factors to Efavirenz Disposition. PMC. 1 indexed citations
16.
Masters, Andrea R., Brandon T. Gufford, Jessica Bo Li Lu, et al.. (2016). Chiral Plasma Pharmacokinetics and Urinary Excretion of Bupropion and Metabolites in Healthy Volunteers. PMC. 1 indexed citations
17.
Santa‐Maria, Cesar A., Amanda L. Blackford, Anne Nguyen, et al.. (2015). Association of Variants in Candidate Genes with Lipid Profiles in Women with Early Breast Cancer on Adjuvant Aromatase Inhibitor Therapy. Clinical Cancer Research. 22(6). 1395–1402. 18 indexed citations
18.
Ji, Yuan, Scott J. Hebbring, Yubo Chai, et al.. (2012). Pharmacogenomics of selective serotonin reuptake inhibitor treatment for major depressive disorder: genome-wide associations and functional genomics. The Pharmacogenomics Journal. 13(5). 456–463. 52 indexed citations
19.
Nguyen, Anne, Vered Stearns, Anne F. Schott, et al.. (2007). Estrogen Receptor Genotypes, Menopausal Status, and the Lipid Effects of Tamoxifen. Clinical Pharmacology & Therapeutics. 83(5). 702–710. 31 indexed citations
20.
Ward, Bryan A., Zeruesenay Desta, Tonya J. Roberts, et al.. (2005). Diindolylmethane inhibits indoleamine 2,3-dioxygenase activity in breast cancer cells. Cancer Research. 65. 577–577. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by David A. Flockhart Breakdown of academic impact, for papers by Michelle Whirl‐Carrillo Breakdown of academic impact, for papers by Ron H. N. van Schaik Breakdown of academic impact, for papers by Stuart A. Scott Breakdown of academic impact, for papers by Kathrin Klein Breakdown of academic impact, for papers by Andrea Gaedigk Breakdown of academic impact, for papers by J. Steven Leeder Breakdown of academic impact, for papers by Jürgen Brockmöller Breakdown of academic impact, for papers by Katrin Sangkuhl Breakdown of academic impact, for papers by Ingolf Cascorbi
Rankless by CCL
2026